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Tissue engineering is a field of research that seeks to create
living tissues with structural and functional properties that mimic
normal tissues and organs. This is accomplished through
manipulation and recombination of cells, proteins (structural as
well as regulatory) and synthetic polymers. To achieve this goal,
tissue engineering draws upon fundamental knowledge
accumulated by basic science, clinical medicine and engineering.
As such, it is inherently interdisciplinary and creates enormous
opportunities for individuals trained in each of these areas to
make significant contributions to the treatment of human disease.
Like many areas of research, tissue engineering was
underway in laboratories around the world long before it was
formally defined. Those familiar with the work of Alexis Carrel
in the early part of thi s century are aware of his pioneering
experiments in animal organ, tissue and cell culture which
reflected a conviction that the cure of human disease might lie in
the ability to regenerate ti ssues in vitro. 1
Today, nearly a century after Carrel's pioneering work, the
annual cost of tissue loss or organ dysfunction in the United
States alone has been estimated at greater than $400 billion
dollars. 2 In addition, the most successful procedures to correct
this loss or dysfunction (i.e., organ transplantation) may be
available to as few as one in ten of those in need. The result is that
during the past five years as many as I 0,000 people died each
year while waiting for organ transplants. 3
During this same period, the extensive use of implantable
devices has taught us much about what can and cannot be
achieved using traditional medical devices. This experience
coupled with dramatic advances in developmental biology,
molecular biology and other basic sciences seem to converge on
the field of tissue engineering. Indeed, the origins of tissue
engineering lie deep within the basic sciences (e.g., biochemistry,
cell and molecular biology, etc.) and medicine, for without
knowledge of tissue and organ function and dysfunction and an
understanding of how individual cells grow and differentiate,
efforts to manipulate that function (i.e., tissue engineering) would
be unfruitful.
Tissue engineering came into formal existence at the first
scientific meeting dedicated to this field, held in 1988 at Lake
Tahoe, California when the following definition was adopted:
"Tissue engineering is the application of the principles and
methods of engineering and the life sciences toward the
fundamental understanding of structure/ function relationships in
normal and pathological mammalian tissues and the development
of biological substitutes to restore, maintain and improve
functions."

During the past 10 years, application of fundamental
knowledge in biology, medicine, and engineering to development
of bioartificial tissues and organs has occurred at a rapid pace.
Innovative research at academic institutions around the world has
spawned tremendous commercial activity in a growing tissueengineered products industry at the interface between the
traditional medical device and biotechnology industries. In this
review, we will briefly describe the status of research and
development in several areas of tissue engineering. While we
have attempted to cover as much of this field as possible, our
treatment is by no means exhaustive. Our goal is to provide a
primer for those unfamiliar with this field and to stimulate their
exploration of the extensive literature in tissue engineering that
now exists.

SKIN
It has been estimated that over 150,000 individuals are
hospitalized annually for burns and over I 0,000 of these
individuals eventually die.4 Burns, as well as pressure ulcers,
decubitous ulcers associated with diabetes and deep lacerations,
are all full thickness wounds because they involve damage to the
deepest layer of the skin (i.e., the dermis) as well as the outermost
layer (i.e. , the epidermis) . When localized and treated properly,
these wounds generally heal without complication, although they
are frequently characterized by wound contraction and scarring.5
When damage is extensive, full thickness wounds are prone to
infection and also permit unregulated water loss from the body .
Moreover, while the epidermal layer of the skin can regenerate,
the dermis cannot.
To date, the most successful treatment for full thickness
wounds has been autogenous skin grafts, i.e., the transplantation
of healthy skin from one site on the patient's body to another
site.6 Unfortunately availability of these grafts is limited since
each graft requires removal of both dermis and epidermis. The
inability of dermis to regenerate restricts the number of times a
site can be harvested.? In addition, the quality of these grafts,
derived as they are from individual donors, can be quite variable.
The limited supply and variable quality of donor skin has Jed
researchers to engineer biological and synthetic equivalents that
mimic important characteristics of skin and are potentially
applicable for treating full thickness wounds.
An important milestone in this regard was achieved in the
late 1970s by Rheinwaid 8 who developed a means of isolating
and culturing keratinocytes from human skin. Using their
approach, the number of keratinocytes isolated from a I cm 2 skin
biopsy could be expanded 10,000-fold in 3 weeks. 4 The resulting
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cultured tissue consisted of sheets of keratinocytes, I 0 to 12 cells
thick, that was suitable for grafting. The primary function of this
tissue, like that of the skin's own epidermis, is to control water
vapor permeability and also to provide a protective barrier against
bacterial infection.9 Unfortunately, these grafts tend to blister and
separate from the underlying host tissue and heal with significant
wound contraction and scarring.s These problems are believed to
stem from the lack of an underlying dermal layer without which
keratinocytes often cannot form anchoring fibrils to underlying
tissue. 5
This has led to investigations of a wide variety of materials
as scaffolds to serve as a dermal equivalent for use in conjunction
with cultured keratinocytes. These scaffolds include reconstituted
collagen lattices, fibroblast-populated collagen lattices, extruded
collagen sheets, collagenlglycosaminoglycan composites and
cadaveric dermis. 7 Collagen is popular because it is a ubiquitous,
naturally-occurring protein, is biodegradable and has limited
antigenicity!O which can be reduced further by processing (e.g.,
crosslinking). 11 In addition, collagen is a substrate for cell
attachment and migration and, therefore, may play a direct role in
wound healing. 12 Moreover, products of collagen degradation are
chemoattractants and can stimulate recruitment of fibroblasts and
other cells to the wound site resulting in more rapid healing and
reduced scarring.s As previously mentioned, human cadaveric
dermis is also used in conjunction with cultured autogenous
keratinocytes as a skin substitute. Importantly, the allogeneic (i.e.,
derived from a different individual of the same species) epidermis
must be removed from the donor tissue, if one wishes to avoid an
immune response by the host. 13
Commercial activity in this area has been brisk with several
products in clinical use in Europe, Canada, and the United States,
e.g., AlloDerm™ (Lifecell Corp,Woodlands, TX), an acellular
human dermis composed of intact native dermal collagen over
which is placed an autogenous skin graft.6 With the advent of
improved methods for tissue cryopreservation, allogeneic dermis
can be stored more effectively and has become more plentiful. It
is now the gold standard in biologic dressings when autogeneic
skin grafts are not available.14
Each of the approaches described above depends upon the
availability of autogenous keratinocytes which must be expanded
in culture prior to use. This process can take several weeks and
represents a significant limitation for treatment of acute full
thickness wounds. To overcome this limitation, allogeneic
keratinocytes have been used with some success. Some
researchers have suggested that these cells may actually provide
an important stimulus to host keratinocytes which migrate and
proliferate at the graft edges, repopulating and replacing the
allogeneic keratinocytes which eventually die.6,?
The current wave of tissue-engineered skin substitutes
include a variety of hybrids that incorporate both synthetic and
biological components. Although polymer-based substitutes are
less resistant to wound contamination and subsequent infection,
they do provide a means of overcoming the inherent variability
associated with allo- and autografts. Uniformity is achieved by
controlling the process by which polymeric components are
fabricated and by adding well characterized biological
components designed to increase biocompatibility. 5 For example,
Biobrane™ (Winthrop Pharmaceuticals, Fountain Valley, CA) is
an acellular skin substitute composed of a nylon mesh that is
coated with porcine type I collagen and overlaid with a thin outer
silicone elastomer membrane. 15 The former supports tissue
ingrowth while the latter acts as a moisture and bacterial barrier.
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Advanced Tissue Sciences (La Jolla, CA) introduced
Dermagraft,TM that includes a dermal component consisting of
woven polyglycolic acid (PGA) mesh seeded with human
neonatal foreskin fibroblasts . These fibroblasts adhere to the
fibers and secrete glycoproteins, glycosaminoglycans, and other
matrix elements which create an extracellular matrix within the
interstices of the mesh.1 4 The mesh is subsequently covered with
cultured autologous keratinocytes. The PGA mesh is resorbable
and disappears over time, leaving behind only biological
components. Dermagraft has performed well in the clinic. 14
Integra Life Sciences (Plainsboro, NJ) has taken a similar
approach with Integra,™ a product that combines a permanent
biological dermal component with a temporary synthetic
epidermal component. Integra's dermal substitute consists of
glutaraldehyde crosslinked bovine type I collagen seeded with
fibroblasts . Other molecules (e.g., chondroitin su lfate
proteoglycans) can be incorporated into the collagen dermal layer
to induce new blood vessels and connective tissue ingrowth.4
This dermal substitute is then covered with a thin polydimethylsiloxane sheet which serves as a temporary epidermis. The
siloxane "epidermis" is eventually removed and replaced with an
autogenous or allogeneic epidermal graft. In fact, the second graft
can be eliminated entirely by seeding epidermal cells directly
onto the dermal component prior to use. 16 Finally, Apligraf,™ a
tissue-engineered living skin substitute developed by
Organogenesis Inc, 17 is in use in Canada and awaits approval for
use in treating venous leg ulcers in the United States.
CARTILAGE

Each year, more than I million Americans undergo surgical
procedures that involve replacement of damaged cartilage.4
These procedures include traditional ap proaches such as
replacement with metal or polymeric prostheses as well as
cartilage transplantation in which autologous cartilage is
harvested from a healthy site, reshaped to suit the desired purpose
and reimplanted. The use of metals or polymers is limited by the
fact that these materials cannot mimic the dynamic and adaptable
properties of cartilage itself and are subj ect to both infection and
degradation due to wear. 18 In the latter approach (i.e.,
transplantation), healthy cartilage from other sites within the
patient must be sacrificed to this procedure. Since these sites are
extremely limited, a great opportunity exists for symbiosis
between biology and material science in creation of tissueengineered cartilage.
The ideal tissue-engineered cartilage is generally envisioned
as consisting of (I) a scaffold fabricated from a bioresorbable
polymer that matches the anatomy of the implant site; (2) an
extracellular matrix containing the appropriate biochemical
signals necessary for cartilage survival and growth; and (3)
healthy autologous chondrocytes (i.e., cartilage-forming cells)
capable of responding to these signals and to mechanical stresses
experienced by cartilage in the appropriate manner. In principle,
this tissue engineered cartilage would be implanted and the
synthetic scaffolding would be resorbed in situ eventually being
replaced with new viable, compatible and mature cartilage. To
achieve this end, the scaffold, the biochemical signals and the
cells must each be considered.
A variety of polymeric biomaterials have been used to
fabricate scaffolds or temporary three-dimensional matrices on
which chondrocytes can be seeded. Such scaffolds are necessary .
to give tissue-engineered cartilage its overall form , to provide
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structural support for individual chondrocytes as is necessary for
their survival and growth, and to permit sufficient nutrient
penetration to maintain chondrocyte viability. Early work using
conventional , nonbiodegradable materials had significant
limitations. For example, silastic materials were used in
reconstructive surgery to form a detailed skeleton . However, they
did not integrate well with host tissues and tended to be extruded
19 R egar d less, these materials are no longer
.
over time.
manufactured for medical use because of recent silicone breast
implant litigation. 19 An alternative approach involves the use of
biodegradable polymers. For example, the first tissue-engineered
cartilage was created in athymic mice using isolated bovine
chondrocytes seeded onto unbraided PGA suture materiat.20,21
Nonwoven PGA and polylactic acid (PLA) meshes also have
been used to create biodegradable cartilage scaffolds.20,22 An
attractive feature of these polymers is that several material
properties (e.g., degradation rate and degree of cell attachment)
can be controlled by modifying polymer composition.18,23
Human cadaveric cartilage has been used, but infrequently,
due to fear of transmitable viruses and resorption following
implantation. 24 Bovine type I collagen also has been used as a
scaffold with some success, resulting in growth of tissues closely
resembling native cartilage histologically, biochemically (i.e. ,
containing sulfated proteoglycans and type II collagen) and
mechanically (i .e., stiffness and compressibility).25 However,
variable quality of commercial bovine collagen and, recently,
health concerns related to bovine prions, 26 are part of a general
trend toward biodegradable polymers like those noted above.
Finally, allogeneic cartilage transplantation has been tried
assuming that acellular cartilage matrix might provide an
immunological barrier to chondrocyte attack. However, these
transplants can elicit an immune response from the host.24
Recent advances in cellular and molecular biology have led
to identification and cloning of several polypeptide growth
factors that influence cartilage and bone formation.21 Bone
morphogenetic proteins (BMPs) are involved in initiation of
cartilage morphogenesis, while transforming growth factor-~ and
insulin-like growth factor-! induce skeletal stem cells to develop
into cartilage. Creative BioMolecules (Hopkinton, MA) and
DePuy (Warsaw, IN) are developing products that incorporating
these regulatory signal proteins into polymeric scaffolds to
modulate chondrocyte function in tissue-engineered cartilage.
Cartilage is formed by specialized cells called chondrocytes.
These cells are critical to the success of any tissue-engineered
cartilage. Chondrocytes grown on polymeric scaffolds secrete
their own extracellular matrix, eventually exhibiting a
morphology similar to that of native cartilage.27 The process of
normal cartilage healing has been studied as a guide to creation of
tissue-engineered cartilage. Damaged hyaline cartilage heals with
formation of fibrocartilage, producing a joint more susceptible to
osteoarthritis. A strategy incorporating cells to replace damaged
tissue could enhance repair by promoting neochondrogenesis
with hyaline cartilage rather than fibrocartilage. As with skin and
cultured autogenous epidermal cells, autogenous chondrocytes
and mesenchymal stem cells which remodel matrix more
effectively, 28 have been cultured for use in cartilage implants.
Companies like Genzyme (Cambridge, MA) are using this
approach to develop processes for harvesting, growing, and
reimplanting autologous human chondrocytes to repair defects in
articular cartilage.
Tissue-engineered cartilage will undoubtedly find its
greatest use in reconstruction of joint surfaces damaged by
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trauma (e.g. , sports injuries) or by degenerative di seases such as
arthritis. However, these grafts may also be used to reconstruct
other cartilagenous structures (e.g., ear, trachea, etc.) .
BONE

The traditional approach to bone repair has centered on
using metals and ceramics in a variety of forms . Bioinert alumina
has been used extensively, as have resorbable ceramic tricalcium
phosphate, porous hydroxyapatite coated metals, bioactive
hydroxyapatites, and certain glasses.21 Alumina interacts little
with surrounding tissues, has a low coefficient of friction, and has
a low rate of wear. However, for materials that come into close
contact with host tissues, the properties of the material surface are
of utmost importance. The gross morphology, microtopography,
and chemistry of the surface determine which molecules, if any,
will adsorb and how cells will subsequently attach and grow.29 In
many instances, the nature of the material surface determines the
nature of the cell response. For example, cell recruitment is
determined by production of appropriate chemotactic factors,
attachment of cells requires the presence of specific extracellular
matrix proteins, and proliferation of cells requires specific growth
factors or cytokines. In order to regulate material-to-cell
interactions either the surface structure must be optimized for
site-specific tissue engineering or the surfaces must be modified
with appropriate biological reagents.
For example, a porous hydroxyapatite coating can be applied
to the surface of a metallic orthopedic implant. This coating, with
pores >100 mm in diameter, allows osteoblast migration into the
coating, supports osteoblast growth, and facilitates bone
".ormatiOn.
. 22Th IS
' strengthens the union between the implant and
surrounding bone. Hydroxyapatite coatings are resorbed over
time and implant performance depends upon ceramic design in
terms of microstructure, pore size, porosity, and surface
chemistry to match the biological and metabolic requirements of
the tissue. 30 Even when these implants are stabilized by
manipulation of the material-tissue interface, as described above,
failure may still occur as a result of friction and wear. Particulate
debris and products of metal corrosion can elicit an immune
response and cause implant failure. The elderly are specifically
susceptible to these types of failure due to compromised response
to stress-induced injury, a less active musculoskeletal system
(which influences bone density), and disease processes associated
with aging.
Bone grafts, either autogeneic or allogeneic, have been used
for several years to treat segmental defects, injury or
malformation of bone. This biological approach has several
limitations. For example, autogeneic bone grafts are limited by
the number of donor sites available and by patient morbidity. In
addition, allogeneic grafts place the patient at risk for
transmission of infectious disease.28
Here too, there is a great opportunity to merge the biological
and material science approaches in tissue engineering. For
example, researchers at Harvard University have studied the
ability of scaffolds constructed of the bioresorbable polymers
PGA, PLA, and copolymers of PGA and PLA to aid in cell
transplantation and regeneration of structural tissue.31 When
autogenous osteoprogenitor cells were cultivated and seeded onto
polymer constructs, large masses of bone formed in vivo
following implantation.31 Vacanti's laboratory has repaired
cranial defects with polymers seeded with periosteal cells.20 After
six weeks, defects showed evidence of both cartilage formation
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and ossification. After nine weeks, defects were filled with
organized bone.
Development in the private sector focuses on use of boneinducing proteins, alone or combined with polymeric scaffolds, to
enhance bone growth . For example, Genetics Institute, Inc
(Cambridge, MA) has developed a recombinant human BMP that
can be used to stimulate bone growth clinically. In addition,
Stryker Biotech, Inc is developing a recombinant form of
osteogenic protein-! (OP-1) that stimulates regeneration of
skeletal tissues (e.g., cartilage and bone) and NOVOS,™ a device
combining osteoinducti ve type I collagen and OP-1 for repair of
bone defects.
PANCREAS
Three-quarters of a million new cases of diabetes are
reported in the United States each year.3 2 Diabetes is a disease
with multiple systemic effects that are related to an inability to
regulate glucose metabolism. In a significant number of cases, the
primary problem is one of insufficient insulin production by cells
in the pancreas and thus the appropriate treatment is exogenous
administration of insulin at periodic intervals to control blood
glucose levels. Unfortunately, systemic effects of diabetes remain
a major cause of illness and death in individuals suffering from
this disease.32 It is now generally accepted that periodic
administration of insulin, particularly when self-administered and
requiring strict patient compliance, cannot provide the tight
control necessary to maintain blood glucose levels within normal
limits. 33 Such tight control of blood glucose can only be achieved
by a system that can rapidly sense changes in blood glucose and
respond equally rapidly by secreting insulin in response to those
changes. At present, the only system that can achieve this is the
pancreatic islet itself.
Clinical successes in pancreatic islet transplantation clearly
demonstrate that regulation of blood glucose can be restored in
patients with diabetes if pancreatic islet function can be replaced.
Indeed, pancreatic islet transplantation is now an approved
treatment for diabetes. However, this procedure is expensive, and
routinely done in only a few medical centers in the country (e.g.,
the University of Minnesota). In addition, islet transplantation is
not suitable for all patients since it requires that
immunosuppressants be used throughout the remainder of the
patient's life to control transplant rejection and recurrence of the
autoimmune processes believed to participate in the etiology of
diabetes .34
Research, therefore, has emphasized development of a
bioartificial pancreas that would be implantable and offer a
permanent solution to the control of glucose metabolism. In
addition, this device would provide complete immunoisolation
such that allo- or even xenogeneic islets could be implanted
·
without dependence on Immunosuppressants.3536
Early devices were perivascular devices into which
pancreatic islets were placed in a chamber surrounding a coiled
tube connected to the patient's circulatory system. The patient's
blood would flow through this tube, composed of a
semipermeable membrane, permitting free diffusion of low
molecular weight molecules (i.e., nutrients and insulin) but
restricting movement of antibodies and immune cells. Devices of
this type could control blood glucose effectively for up to five
months in pancreatectomized dogs.3 7
As an alternative to integration into the circulatory system,
with inherent problems associated with thrombosis and the like,
0
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an intratissular approach has been undertaken by many
investigators. For example, rat islets, immunoisolated by
suspension in alginate (a polysaccharide) and sealed within
semipermeable hollow fiber membranes, have been placed in the
peritoneal cavities of diabetic mice.38 Blood glucose levels of
these mice were maintained within the normal range for 2 months
and the implant was tolerated well in the peritoneal cavity. This
is of great importance since formation of a fibrous capsule would
be expected to progressively reduce diffusion of nutrients into
and insulin out of the device.
More recently, islets have been encapsulated in injectable
microspheres
(<
0.5
mm
diameter).
Microsphere
biocompatibility is critical in this approach because formation of
a fibrous capsule around the microspheres would impede
diffusion of insulin as well as nutrients and waste products across
the tissue-microsphere interface. Microcapsules are commonly
made of hydrogels. The polysaccharide alginate is of particular
interest because of the extremely mild conditions under which
alginate microspheres can be formed. Alginate can also be coated
with polyanions, such as poly lysine, to alter the charge properties
of the micro sphere coating or with additional layers of alginate if
thicker coatings are desired. Such coatings can affect flow of
nutrients and wastes, mechanical strength, and biocompatibility
of the resulting microspheres. Results of in vivo studies with
alginate have been promising but somewhat variable, probably
the result of inconsistencies in the purity of the alginate used.39
In some cases, rodents treated with these microencapsulated
pancreatic islets maintained normal blood glucose levels for over
2 years. 40 .4l
In a recent study with dogs, blood glucose levels dropped
within 24 hours of implanting intraperitoneal microencapsulated
islets. Blood glucose levels were maintained within the normal
range for up to 6 months. 42 Thereafter, gradual deterioration in
glucose tolerance was observed. It has been suggested that the
latter is due, in part, to chronic hypoxia of the avascular islets.
Alternatively, it may reflect a general unsuitability of alginate gel
as a substrate for the prolonged survival of islet cells.
As an alternative to polymers such as alginate, Mahgoub, et
al.43 have proposed using allogeneic amniotic membrane for islet
encapsulation. In a recent study, they transplanted islets
encapsulated in allogeneic amniotic membrane as an
immunoprotective barrier into rodents made diabetic by
streptozotocin. Normal blood glucose levels were maintained
throughout the 6 week study. A simultaneous rise in blood insulin
levels was also noted. Histopathologic study of encapsulated
islets at the end of the study showed viable islets and no evidence
of inflammatory infiltration of the capsule or islets. Significantly,
neovascularization of the capsule wall, i.e., the amnion, was
routinely observed and it has been suggested that this may
enhance survival of transplanted islets.44
Commercial activity in this area has increased recently with
companies such as Neocrin (Irvine, CA), Metabolex (Hayward,
CA), VivoRx (Santa Monica, CA) and Islet Technologies, Inc
(Minneapolis, MN) developing various forms of encapsulated
porcine or human pancreatic islets to treat type I diabetes. Gore
Hybrid Technologies, Inc (a subsidiary of WL Gore &
Associates, the Tucson, Arizona-based maker of expanded
polytetrofluoroethylene (PTFE) materials used for vessel
replacement, soft-tissue reconstruction and surgical sutures) has
joined with Betagene Corp (Dallas, TX) to create a bioartificial
pancreas in which Betagene's genetically engineered insulin- ·
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producing cells are encapsulated in Gore's thin PTFE
membranes.
LIVER

Liver failure is a major cause of death in the United States
(e.g., -27,000 deaths reported in 1990). Liver transplantation,
either partiaJ45 or whole organ, 46 remains the treatment of choice
for this disease since no alternative t herapies curren tl y exis t .47
Unfortunately, many patients who are in need of liver transplants
are not good candidates for this procedure due to underlying
medical conditions such as metastatic cancer, concomitant
infection, or active alcoholism. 48 Conversely, the number of
donor livers available for transplantation is quite limited
(-3,000/year). Moreover, many patients who do qualify for liver
transplantation die while waiting for a suitable donor organ. 49 For
each of these groups of patients a temporary replacement of
critical hepatic function (i.e., a bioartificial liver) would be of
tremendous value. 50
Development of an artificial liver has roots which can be
traced back about 40 years. Early efforts in this area were
nonbiological and focused on replacing the detoxifying functions
of the liver. These technologies were essentially modifications of
traditional hemoperfusion, 5! hemodialysis, 52 and plasma
exchange53 which used charcoal and a variety of resins to remove
toxins from the patient's blood based on molecular weight or
solute affinity. While significant detoxification of blood can be
achieved using this approach, the effectiveness of these systems
is ultimately limited by the inability to replace other liver-specific
functions such as biotransformation and biosynthesis. 54
Recognizing this, alternative approaches to replacement of
. cross hemo d'Ia I ysis
. 55
hepatic function have included xenogeneic
and extracorporealliver perfusion. 56 These efforts are plagued by
problems associated with host immune responses. 57
Simultaneous advances in our understanding of liver function,
particularly at the cellular level (i.e., the hepatocyte), and in
materials science have made the concept of a bioartificialliver for
use as a bridge-to-transplant a reality .58 While researchers have
taken decidedly different approaches to bioartificial liver design,
all use biological components in a polymeric framework to create
what can be called hybrid systems. State-of-the-art membrane
technology creates an effective barrier between the hepatocytes
and the host's immune system.58 Semipermeable membranes
permit diffusion of small molecules like nutrients and toxins to
pass but restrict the movement of cells and immunoglobulins.
This enables devices to be used in clinical settings without
immunosuppression. 59 This is a major advantage over traditional
hepatocyte transplantation and other support techniques such as
crosscirculation and extracorporeal liver perfusion. However,
several problems remain including the compatibility of materials
that come into contact with the patient's blood or tissues 60 and
the difficulty associated with maintaining normal hepatocyte
viability and function at the high cell density necessary to insure
clinical utility.61
Several groups are developing impl antable systems
composed of viable hepatocytes and a variety of supports. These
.
. bea d s, 62 ·63
include hepatocytes grown on coated microcamer
hepatocyte spheroids,64,65 hepatocytes microencapsulated in gel
droplets,59,67-69 and hepatocytes immobilized on porous,
biodegradable polymeric substrates.7° These devices suffer from
several disadvantages. They are permanent and, as such, must
replace liver function for the life of the patient. In addition, their
0

0
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success depends upon rapid vascularization following
implantation.71 This is necessary to insure hepatocyte viability
and function, but is difficult to achieve.
Extracorporeal bioartificial liver devices circumvent these
problems quite effectively since they are not implanted and need
not provide permanent replacement of liver function. These
devices have their origins in traditional hemodialysis and, over
the years, have taken many forms. For example, Matsumura, ~t
aJ.72 developed an extracorporeal device that used rabbit
hepatocytes in suspension. These xenogeneic hepatocytes were
isolated from the patient's blood by a semipermeable cellulose
acetate membrane that prevented large molecular weight proteins
produced by the rabbit hepatocytes from crossing the membrane,
thus reducing the risk of an immunological reaction in the patient.
The primary limitation to use of this, otherwise, elegant system
was its short life span. Nearly continuous replacement of
suspension bioreactors was necessary to maintain clinical
effect. 73
Recently, work has taken parallel tracks focusing on the
design of more efficient bioreactors that increase the number of
hepatocytes that can be incorporated into the device while
maintaining appropriate molecular exchange or on development
of improved methods of sustaining hepatocyte function to extend
the useful life of these devices. A significant advance in the
former has come about through the use of hollow fiber
technology. Hollow fiber cartridges consist of two compartments.
One compartment is composed of numerous small tubes or
capillaries which pass through the device. The second,
extracapillary, compartment surrounds the capillaries. The
capillaries themselves are made of semipermeable membranes
that permit free diffusion of small molecules (e.g., nutnents,
metabolic byproducts, etc.). In typical systems, hepatocytes are
seeded into the extracapillary compartment while blood, plasma
or culture medium flow through the capillaries to provide
essential nutrients to the cells. While cells can be suspended in the
extracapillary compartment, it is clear that hepatocyte attachment
both to other hepatocytes and to extracellular matrix proteins such
as collagen 74 and fibronectin6 2 can have a beneficial effect on
hepatocyte function. Hepatocytes also have been cocultured with
other cells in an effort to provide a microenvironment that more
closely mimics that of the hepatocyte in vivo. Although the
concept of coculturing is not new, its incorporation into the
design of bioartifical liver devices has emerged only very
recently. For example, Gerlach and colleagues have developed a
three dimensional array of interwoven capillaries as a novel
coculture bioartifical liver device.7 5 Yarmush, et ai. 76 have
cultured hepatocytes between two layers of collagen and
demonstrated that, under such conditions, hepatocytes assume a
bipolar morphology and form small channels that resemble bile
canaliculi suggesting a high level of hepatocyte differentiation.
At the University of Minnesota, work by Hu, et ai. 77 has led
to the development of a novel hollow fiber bioreactor-based
bioartificial liver device.7 7 In this device hepatocytes are first
suspended at high cell density in a solution of bovine type I
collagen and subsequently inoculated into the lumens of the
hollow fibers. Following spontaneous collagen fibrillogenesis,
the resulting hepatocyte/collagen matrix undergoes contraction,
which creates a channel through which nutrient solutions can be
delivered. The patient's blood is passed through the compartment
surrounding the semipermeable hollow fibers containing the
collagen entrapped hepatocytes. The gel entrapment bioartifical
liver has undergone extensive testing in vitro. Stable rates of
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oxygen consumption, 78 ·79 insulin uptake,79 albumin
production,79,80 ureagenesis,79 lidocaine metabolism,81 and
bilirubin conjugation8 2 have been demonstrated in vitro for
periods of up to 14 days.
This technology forms the basis for Minnesota-based
Algenix, Inc which plans to begin phase I clinical trials during the
next year. Organogenesis Inc, also is active in this area and has
formed a research and development partnership with a group at
Massachusetts General Hospital led by Dr. Matrin Yarmush, to
develop a liver-assist device as a bridge-to-transplant. Finally,
VivoRx, Inc, has joined with HemoCleanse, Inc pairing VivoRx's
encapsulated porcine liver cells (i.e. HepatoRx) with
HemoCleanse's liver-assist device (the BioLogic-O-r® System).
NERVE REGENERATION

Approximately 40,000 Americans are treated for nerve
damage annually. 2 Peripheral nerve regeneration is a complex
process. Unlike most other cells of the body, mature neurons
cannot divide. For successful regeneration to occur, axons must
extend over large gaps in nerve injuries and must reestablish their
original connections. Thus, regeneration of peripheral nerves
often requires intervention to be successful. Functional
regeneration of the peripheral nervous system has been a
challenge for over one hundred years8 3 and since this goal has yet
to be achieved, research continues to develop methods which aid
in nerve regeneration. Current strategies for repairing injured
peripheral nerves include suturing and nerve grafting. 83 Suturing,
however, is limited to nerve injuries with gap sizes of a few
millimeters. In addition, axons can become blocked, disorganized
or entangled into neuromas at the suture line, resulting in loss of
function. Use of nerve grafts helps overcome the problem of
bridging large gaps. The first successful nerve transplant of any
kind was reported in 1870 by Phillpeaux and Vulpain.83 At that
time, researchers believed that Schwann cells were capable of
regenerating from the distal portion of a severed nerve.
Subsequent work revealed that regeneration began as an
outgrowth of axons from the proximal end, while the distal
portion began to degenerate. Additionally, the nerve graft was
seen to degenerate as well.83
Nevertheless, this technique resulted in some success,
because the graft seemed to provide the needed pathway for axons
to grow from the proximal end towards the distal end of the
severed nerve before it had degenerated completely. At present,
nerve auto grafts are used clinically, but availability of graft
material is limited. 84 Other disadvantages include mismatch of
damaged nerve and graft dimensions and loss of function. These
limitations have led researchers to explore possibilities of tissue
engineered approaches.
A technique referred to as nerve tubulization was developed
in the late 19th century to promote nerve regeneration. This
process involves insertion of the proximal and distal ends of the
severed nerve into the luminal space of a tubular structure. The
nerve ends can be sutured, glued or simply inserted into the tube
in order to confine the nerve stumps. Sutureless techniques have
the advantage of limiting nerve disruption at the point where they
enter the tube. The first success was reported in 1882 by Vanlair
who used tubes made from decalcified bone to bridge a 3 em gap
in the sciatic nerve of a dog.83 Nerve tubulization offers a number
of advantages over previous methods of nerve repair. The main
advantage is that tubes provide a controlled environment for
regenerating nerves. They also protect the nerve from
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surrounding tissues and reduce extraneural invasion and scarring
of the nerve. Finally, tubes for use in this procedure can be
modified as needed to bridge gaps of varying lengths.
Researchers have shown that severed nerves separated by narrow
gaps are bridged by blood clots that form between nerve
stumps.83 These blood clots contain a fibrin matrix that provides
a direct pathway for axons to advance from the proximal to the
distal end. In addition, recent studies confirm that the
extracellular matrix which forms within tubes provides an
essential scaffolding for outgrowth of regenerating nerves. 85
Tubes also provide a confined pathway for regenerating fibers to
grow and help prevent problems caused by misdirected axonal
growth.
Many materials have been used for nerve tubulization ,
including: arteries, veins, muscle, fat, bone, collagen, polyester,
rubber, silicone and stainless steel. For a more in depth list, an
extensive table showing the materials used and their
corresponding histories can be found in a review by Fields, et
aJ.83 Silastic™ (silicone rubber) has been studied extensively for
tubulization because of its inert and elastic properties. In the late
1960s, Ducker and Hayes experimented with Silastic™ in
repairing peripheral nerve injuries of dogs and chimpanzees and
concluded that a thin Silastic™ tube provided the best material
repair of peripheral nerves.8 2 Silastic™ tubing remains the most
commonly used material for nerve tubulization. However, like
many of the materials used, Silastic™ can provoke an
inflammatory response due to tissue incompatibility or
mechanical irritation.86 For this reason, researchers continue to
search for alternative materials for use in this procedure.
The benefits of nerve tubulization are most pronounced
during early stages of nerve regeneration. Therefore, researchers
have studied the possibility of using tubes made of bioresorbable
materials. Collagen is considered a potential material for nerve
tubulization, because it is an important component of
extracellular matrix and can be easily manipulated into a porous,
biodegradable materiaJ.83 Adjuncts are used in tubulization to
further promote nerve regeneration by providing a physical
substrate for axonal and cellular outgrowth. For example,
addition of trophic factors appears to sustain and orient axonal
growth. 83 Experiments from the early 1940s reveal that a
principal factor promoting regeneration is contact between the
growth cone and the substrate. 83 These findings emphasize the
possible value of using extracellular matrix proteins like laminin
or collagen as adjuncts. Tubes filled with laminin and other
extracellular matrix components yield a greater incidence of axon
regeneration across gaps than unfilled tubes. 87 Laminin is
associated with the basal lamina of Schwann cells and is part of
the normal substrate for axonal outgrowth during development
and regeneration.88 In experiments using bioresorbable nerve
tubes filled with a gel containing 80% laminin combined with
collagen and heparin sulfate proteoglycan, regenerated axons
were discovered after two weeks. In contrast, control cases with
empty tubes showed no axons after two weeks. 87 These results
suggest that regeneration can be accelerated by providing a
suitable substrate for cellular outgrowth. Collagen is a matrix
molecule secreted by fibroblasts during regeneration that
provides a scaffold for repair of severed nerves in vivo. Thus,
tubes filled with 3-dimensional collagen matrices (i.e., collagen
gels) have been studied as templates for nerve regeneration.
These gels are comprised of a loose network of collagen fibrils
that are typically 99% fluid. Axon outgrowth seems considerably ·
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more rapid in tubes filled with collagen gels . than in empty
tubes. 89
Further improvements in nerve regeneration have been noted
when collagen is chemically crosslinked.83 Tranquillo, et al., at
the University of Minnesota are currentl y developing collagen
gels comprised of axially aligned collagen fibrils. Alignment is
ac hieved by allowing fibrillogenesis in the presence of a hi gh
strength magnetic field . Initial res ults suggest that nerve
regeneration is enhanced in aligned (i.e. noni sotropic) collagen
networks compared to un aligned (i.e. isotropi c) collagen
networks.90
Shine, et al. examined the ability of tubes filled with cultured
neurons suspended in a collagen matrix to promote axon
regeneration.9 1 Neurons and glial cells produce growth factors
which help regulate development, growth and regeneration in the
nervous system. Enhanced regeneration is believed to occur
because nerve tubulization confines these factors, enabling them
to promote growth.83 In a recent study, Guenard, et al. found that
tubes filled with Schwann cells seeded in matrigel , a complex
extracellular matrix derived from a mouse tumor, supported
extensive peripheral nerve regeneration.84 Schwann cells are
strong promoters of axon regeneration because they secrete
several trophic factors, express cell adhesion molecules and
synthesi ze extracellular matrix . Use of Schwann cell seeded tubes
is currently being investigated as a way to promote regeneration
in the central nervous system.92 Nerve regeneration is a complex
process and, although tremendous experimental strides have been
made, a more comprehensive understanding of the factors that
govern this process must be achieved before tissue engineered
approaches will replace currently accepted therapies such as
nerve suturing and nerve grafting.
BLOOD VESSELS

Atherosclerosis is the leadi ng cause of death and serious
illness in economically developed countries throbgh its sequel of
coronary artery and cerebrovascul ar di sease. Treatment of
coronary artery disease often involves bypass surgery in which
blood is diverted around an occluded vessel (i.e., the vessel is
bypassed) using a suitable conduit.
Autogenous vein grafts remain the gold standard for such
procedures, but are not always available. A variety of synthetic
vascul ar grafts composed primarily of woven polyethylene
terephthalate (PET) or thermally expanded PTFE have been used
for arterial replacement. 93 Performance of these grafts,
particularly when used to replace small vessels such us coronary
arteries (i.e., < 4 mm diameter), has been limited by the high
incidence of occlusion, commonl y from thrombosis.9 4-96 To
reduce thrombosis, grafts trad itionall y have been made from
relatively inert materials and often are coated with heparin (a
natural anticoagulant) or other macromolecules that reduce
interaction of plasma proteins and blood cells (e.g., platelets) with
the graft surface. 97 .98
In native tissue, these properties are attributable to vascular
endothelial cells that form the luminal lining of the blood vessel.
These endothelial cells form a contact-inhibited monolayer of
highly flattened cells that present an inert nonthrombogenic
surface to the blood stream and ensure that circulating blood cells
do not adhere to blood vessel walls.99 Various investigators have
endeavored to improve performance of vascular prostheses by
seeding them with autologous endothelial cells before implantation .100·10l However, vascular graft surfaces tend to be poor
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substrates for cell adhesion and the fraction of seeded cells which
adhere in the time frame dictated by graft implantation procedures
is relatively low. 102 A number of investigators have developed
hybrid vascul ar grafts by precoating polymeric vascular
prostheses with extracellular matrix proteins such as collagen or
fibronectin in an attempt to increase endothelial cell adhesion. 103t05 Unfortunately , in the absence of specific surface
modificati on, binding and retention of proteins by synthetic
vascul ar grafts is poor and endothelial seeding efficiency is only
marginally improved. t06
Exposure to a high energy gas plasma (i.e. , plasma
discharge) is one way to modify surface characteristics of
biomaterials. 107 Surface modification by plasma discharge in
oxygen can enhance the ability of vascular grafts to bind and
retain fibronectin and laminin . t08 This is associated with
increased endothelial cell attachment. 108 Others have
immobilized proteins to graft surfaces using photoreactive
crosslinkers containing the phenyl azide group. 109
As an alternative to using large intact proteins such as
fibronectin, many investigators have taken a synthetic approach
that uses well-defined synthetic peptides whose sequences are
derived from naturally occurring extracellular matrix proteins.
The University of Minnesota has been at the forefront of efforts
to identify and characterize cell adhesion-promoting sequences in
extracellular matrix proteins and of efforts to use synthetic
peptides based on these sequences to create hybrid biomaterials
for ti ssue engineering applications. For example, work by
Huebsch, eta!. has identified a no vel sequence in fibronectin (IleGlu-Pro-Pro-Arg-Ala-Arg-Ile) that promotes adhesion, spreading
and motility of vascular endothelial cells. 110 A photoreactive
analog of this peptide has been developed that retains its
adhesion-promoting activity following covalent coupling to a
variety of biomaterial surfaces . 111 Endothelial cells seeded onto
materials to which this peptide has been coupled resist
detachment when exposed to physiological shear rates in vitro
(unpublished observations, P. Gairola). A hybrid peptide coated
PTFE graft is being testin g as an adj unct to autologous
endothelial cell seeding in femoral artery grafts in dogs.
Miwa, et a!. 11 2 have taken a different approach to creation of
a hybrid vascular graft that simultaneously addresses
biomechanical and biological aspects of graft design. Miwa's
experimental graft co ntains three elements: endothelial cells
which form the internal lining of the graft, an artificial basement
membrane which supports thes e cells and a polyurethane
elastomeric graft whose compliance matches that of the native
artery.
These methods represent a continuum of both engineering
and biology that has fueled refinement of existing materials and
development of new materials that interact in predictable ways
with protei ns and cells of the body.
Weinberg and Bell 113 are pioneers in the development of a
bioartificial artery. Their work has focused on reconstitution of
type I collagen in tubular molds containing cultured vascular
endothelial cells, smooth muscle cells and fibroblasts in layers
that approximate the trilaminar structure (i.e., intima, media,
adventitia) of the vessel wall. Early bioartificial arteri es Jacked
the mechanical strength necessary to withstand the physiologic
arterial blood pressures , and woven PET sheaths were
incorporated into the design to provide the requisite mechanical
strength. In addition, while these vessel analogs superfici ally
mimicked the laminar structure of the vessel wall, the
organization of these layers did not completely mimic that found
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in natural arteries. Specifically the smooth muscle cells and
collagen fibrils of the medial layer were randomly oriented,
whereas the orientation of collagen and smooth muscle cells in
the vessel media is decidedly circumferential. This
circumferential orientation is crucial to the mechanical strength of
natural arteries and efforts are now underway to mimic this
orientation in attempts to create a stronger bioartificial artery. For
example, Kanda, et a!. 114 have used cyclic mechanical strain
which approximates that experienced by cells of the vessel wall
in vivo to mechanically condition bioartificial arteries. They have
demonstrated that such conditioning can induce circumferential
alignment of both collagen and vascular smooth muscle cells in
vitro. Tranquillo, eta!. recently demonstrated that circumferential
alignment also could be induced by exposing the bioartificial
artery to a high strength magnetic field during collagen
fibrillogenesis.ll5 The resulting circumferential alignment of
collagen correlated with circumferential alignment of smooth
muscle cells and increased mechanical strength. L'Heureux, eta!.
have observed that circumferential alignment occurs when
compaction of a simple bioartificial artery is constrained around
a mandreJ.ll6 Tranquillo, et a!. have extended this work by
correlating this alignment with a significant increase in
mechanical strength. 115
Despite these efforts, a general lack of mechanical strength
remains the primary limitation to use of these bioartificial arteries
although Auger, et a!. 117 recently described a technique for
developing a bioartificial artery that can withstand physiological
pressures in vitro and in vivo. This approach, in which sheets of
smooth muscle cell-populated matrices are rolled into tubes and
then cultured for an extended period of time, is accompanied by
extensive matrix remodeling. This is consistent with recent work
by Ogle and Mooradian (unpublished observations) suggesting
that development of mechanical strength in a bioartificial artery
occurs over time and depends upon specific interactions between
smooth muscle cell integrins and coilagen. A greater
understanding of this remodeling process at the cellular and
molecular levels may well provide the critical insight around
which new strategies for blood vessel engineering can be
developed.
While several groups in academic institutions and
companies around the world continue research in this area, the
complex mechanical and biochemical functions that blood vessels
perform remain beyond the reach of current technology. Indeed,
most commercial activity focuses on developing acellular
collagen-based vascular grafts that are gradually repopulated and
remodeled by host cells. Both Organogenesis Inc and Advanced
Tissue Sciences (La Jolla, CA) are developing collagen-based
small caliber vascular grafts which appear likely candidates for
clinical use in the foreseeable future.
Availability of biodegradable polymers (e.g., PLGA) as
well as protein-based polymers has led to renewed interest in
development of hybrid bioartificial arteries like those described
above, but which incorporate a biodegradable scaffold of some
form . ll8 , 119 These scaffolds would provide the requisite
mechanical properties necessary for clinical use but ideally would
be biodegradable so that over time, the implant would be
remodeled and incorporated into the patients vascular system.
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SUMMARY

In several areas (e.g., skin, pancreatic islets, and liver)
clinical use of tissue-engineered products is either underway
(e.g., skin) or likely within the next two to five years (e.g., islets,
liver, and cartilage). In others areas (e.g., bioartificial artery), the
complex structural and functional needs of engineered tissue are
such that the horizon is less well defined. Nonetheless,
fundamental knowledge is added daily creating new
opportunities nearly as rapidly as existing knowledge can be
applied. Fundamental research in new materials, particularly in
biopolymers, promises to revolutionize the materials science of
tissue engineering and, by extension, our approach to tissue
engineering. Advances in genetic engineering and gene therapy
make it possible to manipulate directly the functional properties
of cells subsequently incorporated into artificial organs, perhaps
creating high performance bioartificial tissues or organs with
increased functional capabilities or a greater ability to endure less
than optimal environments (e.g., hypoxia due to limited
vascularization) encountered by implanted tissues or organs.
Tissue engineering will create tremendous opportunities for
partnerships between academia and industry in transferring fruits
of innovative research to the clinic. The rapid pace of
development is overwhelming entities charged with regulating
tissue-engineered products. While bioartificial tissues and organs
may be viewed as devices they also can be viewed as biological
reagents. The regulatory burden created by this dual nature is
compounded by the limited experience in this area possessed by
companies and the Food and Drug Administration. This will
affect progress of bioartificial tissues and organs toward
commercialization. Of equal importance is how engineered
tissues and organs will fare in the healthcare marketplace. In
areas such as development of a bioartificial liver as a bridge to
transplant, alternative therapies do not currently exist, and
acceptance seems clear. In other areas (e.g., bioartificial
pancreas, skin, and artery), alternatives, while not ideal, exist and
standards of cost-effectiveness and clinical benefit, compared to
accepted treatments will determine if these products find there
way to the clinic. 120
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